Leading the way to safer medication

Αxicabtagene ciloleucel

Therapeutic Indications

Αxicabtagene ciloleucel is indicated for:

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Irrespective of gender only Adults (18 - 65 years old)

Αxicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 68 ml once

Primary mediastinal large B-cell lymphoma (PMBCL)

Irrespective of gender only Adults (18 - 65 years old)

Αxicabtagene ciloleucel is indicated for the treatment of adult patients with primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 68 ml once

Contraindications

Active ingredient Αxicabtagene ciloleucel is contraindicated in the following cases:

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines

MPI, EU: SmPC 2020: SPC: YESCARTA Dispersion for infusion

< Previous: Overview
Next: Precautions >